纵隔淋巴瘤质子治疗中深吸气屏气的系统综述:PTCOG淋巴瘤小组报告与推荐
本系统综述依据PRISMA指南检索PubMed数据库,纳入8项研究,比较质子自由呼吸(FB)和/或质子深吸气屏气(DIBH)与IMRT-DIBH在纵隔淋巴瘤患者中的剂量学差异。结果显示质子治疗(FB或DIBH)在心脏、肺、乳腺及积分剂量上优于IMRT-DIBH,且质子DIBH较质子FB可进一步降低肺和心脏剂量。
要点
- 质子DIBH较IMRT-DIBH在8项研究中7项降低平均心脏剂量,1项相似。
- 质子DIBH较质子FB在4项研究中降低平均心脏剂量,3项降低平均肺剂量。
- 质子FB与质子DIBH积分剂量相似,均显著低于IMRT-DIBH。
核心结论
- 综合考虑心脏、肺、乳腺及积分剂量,质子治疗(FB或DIBH)优于IMRT-DIBH。
- 质子DIBH较质子FB可进一步降低肺和心脏剂量,取决于纵隔病变位置及器官保护和靶区覆盖的优先次序。
研究设计与样本
- 遵循PRISMA指南的系统综述,检索PubMed数据库,截至2021年4月共纳入8项研究。
- 纳入标准为纵隔淋巴瘤患者中质子FB和/或质子DIBH与IMRT-DIBH的剂量学比较研究,排除病例报告。
- 比较类型包括:质子FB vs IMRT-DIBH(n=5)、质子DIBH vs 质子FB(n=5)、质子DIBH vs IMRT-DIBH(n=8)。
- 参数包括平均心脏剂量(MHD)、平均肺剂量(MLD)、平均乳腺剂量(MBD)等,平均剂量绝对差异>1 Gy视为有临床意义。
主要发现
- 质子FB vs IMRT-DIBH(5项研究):MHD在2项研究中降低,2项相似(差异<1 Gy),1项升高;MLD和MBD分别在3项和4项研究中降低。
- 质子DIBH vs 质子FB(5项研究):MHD和MLD分别在4项和3项研究中降低,MBD保持相似。
- 质子DIBH vs IMRT-DIBH(8项研究):MHD在7项研究中降低,1项相似;MLD和MBD分别在8项和6项研究中降低。
- 质子FB与质子DIBH的积分剂量相似,且两者均显著低于IMRT-DIBH。
关键数值与推荐
- 平均剂量绝对差异>1 Gy被判定为有临床意义。
- 质子DIBH较IMRT-DIBH在8项研究中7项降低MHD,8项降低MLD,6项降低MBD。
- 质子DIBH较质子FB在5项研究中4项降低MHD,3项降低MLD,MBD保持相似。
- 质子FB较IMRT-DIBH在5项研究中2项降低MHD,3项降低MLD,4项降低MBD。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To systematically review all dosimetric studies investigating the impact of deep inspiration breath hold (DIBH) compared with free breathing (FB) in mediastinal lymphoma patients treated with proton therapy as compared to IMRT (intensity-modulated radiation therapy)-DIBH. MATERIALS AND METHODS: We conducted a systematic review in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guideline using the PubMed database to identify studies of mediastinal lymphoma patients with dosimetric comparisons of proton-FB and/or proton-DIBH with IMRT-DIBH. Parameters included mean heart (MHD), lung (MLD), and breast (MBD) doses, among other parameters. Case reports were excluded. Absolute differences in mean doses > 1 Gy between comparators were considered to be clinically meaningful. RESULTS: As of April 2021, eight studies fit these criteria (n = 8), with the following comparisons: proton-FB vs IMRT-DIBH (n = 5), proton-DIBH vs proton-FB (n = 5), and proton-DIBH vs IMRT-DIBH (n = 8). When comparing proton-FB with IMRT-DIBH in 5 studies, MHD was reduced with proton-FB in 2 studies, was similar (<1 Gy difference) in 2 studies, and increased in 1 study. On the other hand, MLD and MBD were reduced with proton-FB in 3 and 4 studies, respectively. When comparing proton-DIBH with proton-FB, MHD and MLD were reduced with proton DIBH in 4 and 3 studies, respectively, while MBD remained similar. Compared with IMRT-DIBH in 8 studies, proton-DIBH reduced the MHD in 7 studies and was similar in 1 study. Furthermore, MLD and MBD were reduced with proton-DIBH in 8 and 6 studies respectively. Integral dose was similar between proton-FB and proton-DIBH, and both were substantially lower than IMRT-DIBH. CONCLUSION: Accounting for heart, lung, breast, and integral dose, proton therapy (FB or DIBH) was superior to IMRT-DIBH. Proton-DIBH can lower dose to the lungs and heart even further compared with proton-FB, depending on disease location in the mediastinum, and organ-sparing and target coverage priorities.
引用
- Patel CG, Peterson J, Aznar M, et al. Systematic review for deep inspiration breath hold in proton therapy for mediastinal lymphoma: A PTCOG Lymphoma Subcommittee report and recommendations. Radiother Oncol. 2022. PMID: 36252635. doi:10.1016/j.radonc.2022.10.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。